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, trevor J. pugh 6, 7 , michael D. taylor 1, 2, 12, 15, 19 , martin Hirst 11, 17 , connie J. eaves 8, 10 , benjamin D. simons . Central to our understanding of GBM biology is the idea that tumour initiation, maintenance, and regrowth following treatment are seeded by glioblastoma stem cells (GSCs) 2, 3 . Evidence for a proliferative hierarchy in GBM has been derived from xenotransplantation of specific GBM subsets defined by surface marker expression 2 , genetic lineage tracing in mouse models 3 and, more recently, single-cell RNA sequencing 4, 5 . In parallel, GBMs exhibit substantial intratumoural genomic heterogeneity 6,7 that could theoretically be based in GSCs with variations in growth potential, treatment responsiveness, or invasiveness [8] [9] [10] . However, recent evidence from other systems demonstrates that the intrinsic growth dynamics of a functionally homogeneous population of stem cells are already sufficient to create a wide range of clonal growth behaviours [11] [12] [13] [14] . Therefore, it is as yet unclear whether the heterogeneity of human GBM clones is primarily derived from their genomic heterogeneity, or the stochastic outcome of their hierarchical mode of growth.
DNA barcoding is a methodology that enables the proliferative capacity of individual cells to be resolved within polyclonal populations, with diverse applications in stem cell and cancer biology. Recent investigations using this strategy have already provided crucial insights into the lineage potential of normal stem cells 15 and the proliferative heterogeneity of their transformed counterparts 16 , as well as mechanisms of cancer drug resistance 17 and metastasis 18 . Importantly, characterization of population dynamics in a quantitative and unbiased way can be used to inform a mathematical framework to explain complex behaviours 13, 17 . Here we perform DNA barcoding of primary GBM cells in order to investigate the quantitative behaviours of GSC clones, creating a general, minimal model of GBM growth in which a high degree of intratumoural functional complexity can be derived from a homogeneous population of stem-like cells.
Lineage tracing of human GBM cells
Lineage tracing assays based on genetic mouse models have demonstrated that quiescent stem-like cells promote brain tumour recurrence following chemotherapy 3, 19 . However, it remains unclear how these cells contribute to tumour growth in genetically heterogeneous human GBM 6, 7, 20, 21 . To identify potential differences in tumour cloneinitiating potential, tolerance to chemotherapy and invasion capacity, we made use of a lentiviral barcoding strategy to trace the output of individual cells in vivo 15, 16, 22 (Fig. 1a) . Freshly dissociated cells from primary (GBM-719, -729, -735, -743, and -754) and recurrent (GBM-742) GBMs were transduced with a library of biologically neutral barcodes before their transplantation into the brains of NOD/SCID/IL2Rγ article reSearcH spiked-in controls were included to estimate relative clone sizes from barcode read counts (Extended Data Exome and RNA sequencing of primary tumours identified mutations in common GBM-associated genes (TP53, EGFR, PDGFRA) and signatures of the classical and proneural transcriptional subgroups 20 (Extended Data Fig. 2a, b) . Histologically, xenografts resemble human GBM and have abundant expression of the neural precursor marker nestin 2 ( Fig. 1b and Extended Data Fig. 3a, b) . Consistent with the considerable inter-patient heterogeneity of human GBM 20, 21 , tumours generated from different primary samples differed in proliferative activity, apoptosis rates, growth rates and response to temozolomide (TMZ) chemotherapy (Extended Data Fig. 3c, d ). In the following study, we focused first on GBM-719, for which the largest xenograft dataset was available, using xenografts from other GBMs to test for consistency in their properties.
Growth of GBM cells in vivo was concomitant with expansion in both the injected (ipsilateral) and non-injected (contralateral) hemispheres ( Fig. 1c and Extended Data Fig. 4a, b) . For GBM-719, 1,532 clones (derived from approximately 3% of the barcoded cells) expanded above the detection threshold, with 475 present in both hemispheres. The sizes of these 'surviving' clones were broadly distributed, with the majority remaining small (Fig. 2a) . A further, smaller reduction in clone number was observed upon serial passaging, with a fraction becoming apparent only in the second passage, indicating that some clonogenic cells did not reach the detection threshold within the first passage (Fig. 1d ). These observations suggest that the primary GBM population contained only a subset of cells with continuous tumour-maintaining activity (GSCs). However, the abundance of surviving clones and broad size distributions demonstrate that tumour growth does not rely on the activity of a few tumour-initiating cells 4 
GBM clones are uniformly invasive
We next sought to define the invasive capacity of barcoded GBM clones by comparing clonal composition between the ipsilateral and contralateral hemispheres, the latter representing expansion of invasive cells (Extended Data Fig. 4a, b) . In all experiments, the sizes of clones in both hemispheres were either highly correlated from the first passage onwards, or became highly correlated soon thereafter (Extended Data Fig. 4c ), indicating that clonal behaviour in the contralateral side reflected their behaviour in the ipsilateral side. We then asked whether clones that were exclusively found in the contralateral side have a higher invasive capacity. However, xenografts derived from re-injecting contralaterally collected cells were primarily composed of clones that had been present in both hemispheres in the previous passage (Extended Data Fig. 4d) . It follows that self-renewal and invasion capacity are coincident properties of the same labelled clones within each human GBM. Spatial separation of genetically distinct clones may therefore represent transient variations in local dispersal, which become amplified over time 6, 10, 23, 24 .
Neutral hierarchical growth dynamics
A consistent feature of clone sizes across all passages and between hemispheres was their broad distribution ( Fig. 2a and Extended Data Fig. 4e ). Such functional heterogeneity could derive from engrained 'fitness' advantages of some tumour-initiating cells over others, resulting from heritable genetic or epigenetic alterations 8 . Alternatively, variation in clonal output could result from 'neutral' processes, reflecting the chance outcome of cell fate decisions obtained within an equipotent tumour-initiating population 11, 12 . To discriminate between these possibilities, we looked for evidence of equipotency in the distribution of relative clone size. Remarkably, the distributions were found to be consistent with a negative binomial dependence, as evidenced by the exponential form of the first incomplete moment (Fig. 2b , Extended Data Figs 5, 6 and Supplementary Theory 2). Some xenografts also showed a minority (less than 4%) of large clones that lay outside this distribution ( Fig. 2b and Extended Data Fig. 4g , red arrowhead), a feature that is discussed further below. With clone size distributions across all six patient tumour samples largely characterized by just one parameter (the constant of the exponential), these observations suggest that GBM intratumoural heterogeneity derives primarily from the growth characteristics of a single equipotent cell population rather than an engrained differential fitness of subclones, an unexpected finding given the inter-and intra-patient genomic diversity of GBM and the ongoing genomic evolution observed in xenografts 6, 7, 20, 21 (Extended  Data Figs 5, 6 and Supplementary Theory 3) .
How a negative binomial clone size distribution could arise is an intriguing question. Such behaviour is common in population dynamics and is typically associated with processes involving the sporadic creation of 'individuals' (cells in this case) that, when born, undergo a stochastic process, selecting with equal probability between duplication (birth) or loss (death) and supported by a slow influx from another compartment (immigration)-a 'critical birth-death process with immigration' 25 (Supplementary Theory 3). In the tumour context, this behaviour translates to a proliferative hierarchy in which a slow-cycling stem-cell-like population undergoes serial rounds of invariant asymmetric cell division, giving rise to a self-sustaining, rapidly dividing progenitor population that generates short-lived, non-proliferative progeny ( Fig. 2c and Supplementary Theory 4) .
We then considered the plausibility of strictly invariant asymmetric cell division. As most barcoded clones survive dilution through serial passaging (Fig. 1d) , individual clones at the end of the previous passage are likely to host a multiplicity of stem-like cells. Cell division must therefore also lead to symmetric fate outcomes so that their numbers can accumulate in individual clones. However, so long as asymmetric fate outcomes predominate, the resulting clone size distributions do not depart considerably from the observed negative binomial form (Supplementary Theory 4).
On the basis of a quantitative analysis of clone sizes, we propose that human GBM growth in xenografts is defined by a minimal model involving a defined GSC hierarchy ( Fig. 2c and Supplementary Theory 4). To challenge the model and define the minimal set of parameters governing GBM growth, we used stochastic simulations to compare the predicted clonal dynamics with experimental findings (Fig. 2d-h ,  Supplementary Theory 5 and Supplementary Tables 2-4 ). In assessing the viability of the model, we constrained the simulation using a range of biologically plausible parameters based on the overall expansion of xenografts along with the proportion of actively dividing and apoptotic cells (Extended Data Fig. 3d and Supplementary Theory 5). Over the determined range of parameters, simulations revealed an approximately negative binomial clone size distribution across all serial passages ( Fig. 2e and Supplementary Table 2), consistent with experimental observations. Using the unique barcoding of clones, we assessed correlations of clone size and survival likelihoods across serial passages. Remarkably, the minimal model captured the range of data to a high level of accuracy (Fig. 2f-h 
Two divergent GSC phenotypes
Building on the findings above, we next sought to define the effect of TMZ chemotherapy on clonal dynamics. Analysis of the TMZtreated xenografts clearly distinguished two divergent behaviours: a majority of clones were sensitive to TMZ treatment and present at low abundances ('group A' in Fig. 3a, b) , while a minority were present at frequencies almost an order of magnitude greater, consistent with treatment resistance ('group B' in Fig. 3a, b) . Comparison of the TMZtreated secondary xenografts with the untreated primary xenograft indicated that the sizes of sensitive clones were largely uncorrelated across serial passages, whereas the sizes of the resistant clones appeared to be positively correlated (Fig. 3a) . Notably, the further coincidence of distinct resistant clones in drug-treated replicate xenografts (Fig. 3c, d ) suggests that the resistance phenotype can be pre-existing within the parental population.
On the basis of this classification, we analysed the clone size distribution within each group separately. Sensitive clones maintained an approximate negative binomial dependence (Extended Data Fig. 5a ), Taken together, these results demonstrate that a minority of clones in pre-and post-treatment tumours conform to perturbed growth dynamics, and may constitute a key driver in the clonal evolution of human GBM. We define these outliers as 'group B' clones, and the majority that behave according to the negative binomial distribution as 'group A' .
Epigenetic targeting of distinct GSCs
We next questioned whether the group B phenotype exposes new therapeutic vulnerabilities. Primary GSC cultures 26 established from xenografts maintained a mixture of clones seen in primary, secondary and tertiary passages (Extended Data Light dataset: group A, 95 data points; group B, 15 data points; dark dataset: group A, 117 data points; group B, 15 data points. c, Correlation of the two replicate secondary xenografts shown in a with Spearman's rho indicated. d, Correlation of the two replicate tertiary xenografts shown in b with Spearman's rho indicated. e-f, Correlation of clone sizes obtained from simulations with a subset of clones being resistant to cell death (blue dots) and the remaining clones following unperturbed dynamics (green dots) for a primary and secondary passage (e) and a secondary and tertiary passage (f) (see Supplementary Theory 6.5). S and P cell division rates are set at 0.1 and 1.5 per day, respectively; ε = 10%; apoptosis rate set at 0.7 per day with a 0.5% chance of each clone to show resistance to apoptosis (see Supplementary Theory, Supplementary Table 3 (1) 754 , for which the most data was available, maintained a negative binomial distribution after an approximately sevenfold expansion in vitro, consistent with maintenance of the proliferative hierarchy under culture conditions (Extended Data  Fig. 7d , e and Supplementary Table 6 ). This included the correlations of outlier clones between replicates (Extended Data Fig. 7f ), corroborating the previously observed presence of group B clones in untreated xenografts (Fig. 2b) . Most cultures derived from other xenografts also adhered to a negative binomial distribution once the largest outliers were removed (Extended Data Fig. 8a, b and Supplementary Table 7) .
We next combined in vitro drug selection of the (1) 754 culture with barcode sequencing to determine whether resistance arises proportionately from each clone type (Extended Data Fig. 9a, b) . GSC cultures analysed by assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) identified a shared epigenetic state, leading us to focus on epigenetic targets (Extended Data Fig. 2d ). Cells subjected to drug selection were allowed to repopulate to a similar density as the control, in order to model tumour regrowth following therapy (Extended Data Fig. 9b ). The drug treatments induced a range of changes to clonal dominance patterns (Extended Data Fig. 9c and Supplementary Table 8 ). However, the same negative binomial distribution was maintained in most cases, indicating that the underlying dynamics of group A clones are largely unperturbed (Extended Data Fig. 10a, b) . Notably, a Menin-MLL (mixed-lineage leukaemia) interaction inhibitor (MI-2-2) 27-29 was selective against group B clones, as repopulation following selection derived primarily from group A clones (Fig. 3g, Extended Data Fig. 9d ). By the same logic, and consistent with the requirement for enhancer of zeste homologue 2 (EZH2) in GSC maintenance 30 , we found that an EZH2 inhibitor (UNC1999) was instead selective against group A clones (Fig. 3g, Extended Data  Fig. 9d ). MI-2-2 is growth inhibitory in a polyclonal context, consistent with its specificity for the highly proliferative clone type (Extended Data Fig. 9e ). Targeting both clone types by combining MI-2-2 with an EZH2 inhibitor (UNC1999 or GSK343) was uniquely sufficient to eradicate self-renewal (Fig. 3h, Extended Data Fig. 9f-h ). Consistent with TMZ-induced selection for group B clones in GBM-719, MI-2-2 treatment of TMZ-transformed cells eradicated self-renewal and reduced tumour growth in vivo (Fig. 3i, j, Extended Data Fig. 9i) . Efficacy of the UNC1999/MI-2-2 combination was mirrored in four additional models (G523, G549, G564, G566) even when single-drug treatments did not affect self-renewal, and in GBM-851 primary cells (Extended Data Fig. 9j-n) . Although Menin-MLL inhibition is especially effective in targeting paediatric gliomas that carry histone 3 variant H3.3 mutations (H3.3K27M) 27 , these findings warrant further pre-clinical studies of MI-2-2 in advanced, post-treatment adult GBM.
Discussion
Efforts to define the identity and behaviour of tumour-maintaining cells in human GBM have focused on genetic intratumoural heterogeneity 9,31 , yet the majority of subclonal mutations in cancer may be biologically neutral 14, 32 . At first sight, the emergence of clonal heterogeneity suggests that the evolving mutational landscape may confer a range of fitness advantages on GSCs. However, quantitative analysis of clone sizes indicates that clonal heterogeneity can be explained by robust features of a conserved proliferative hierarchy. In this model, heterogeneity in clonal expansion does not derive from genetic diversity but, in common with other cancer models 11, 12 , emerges as the predictable outcome of fate decisions made by GSCs and their progeny. Given the correlation of human GBM cell transcriptomes with those of normal outer radial glial cells and intermediate progenitors 33 , these results suggest that the initiation of human GBM may be associated with the aberrant reactivation of a surprisingly normal developmental program.
Although the majority of GSC clones adhere to neutral, hierarchical growth dynamics (group A), we identified a minority subset that showed a different growth characteristic (group B). Whether or not group B clones share common molecular features between different patient tumours is currently unknown. Notably, however, these dominant clones are sensitive to an epigenetic drug targeting Menin-MLL (MI-2-2) that was previously shown to be effective in H3.3 mutant (H3.3K27M) paediatric glioblastoma 27 . Together with the fact that adult GSCs can converge into an epigenetic state reminiscent of paediatric GBM owing to selective downregulation of H3.3 expression 29 , it is tempting to speculate that group B clones in adult GBM may share additional epigenetic features of H3.3 mutant paediatric GBM cells and H3.3-low adult GSCs 29 . Alternatively, group B clones may arise from group A clones after a gradual accumulation of genetic mutations that alters their mode of growth 7 . Future studies should target the origin and functional properties of these clones, and assess whether they contribute disproportionately to GBM malignancy.
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MethODS
No statistical methods were used to predetermine sample size. For animal studies, all animals were included for the analysis. Animals from separate litters were randomly and evenly divided between experimental groups to control for animal age. The investigators were not blinded to group allocation during the experiments and outcome assessment. Processing of patient samples. GBM tumour samples were obtained from consenting patients, and all procedures are approved by the Research Ethics Boards at The Hospital for Sick Children (Toronto, Canada), St. Michael's Hospital (Toronto, Canada) and Toronto Western Hospital (Toronto, Canada). Following surgical resection, tumour specimens were immediately subjected to mechanical and enzymatic dissociation in artificial cerebrospinal fluid containing trypsin, hyaluronidase, and kyneuric acid at 37 °C. GSC culture models were established as previously described 26 , and matched to primary GBM tumour tissue by microsatellite genotyping (The Centre for Applied Genomics, The Hospital for Sick Children). GSC cultures were also randomly and intermittently tested for mycoplasma contamination by PCR. For barcoding experiments, primary single-cell suspensions were subjected to magnetic bead depletion to remove cells expressing human CD31 and CD45 markers (130-091-935, 130-045-801, Miltenyi Biotech), thereby excluding endothelial and haematopoietic lineages before lentiviral barcoding. Exome sequencing. For the primary tumour samples, DNA was extracted from flash-frozen primary tumour pieces using an AllPrep DNA/RNA Mini Kit (80204, Qiagen). Genomic DNA libraries from which exons are captured were constructed according to British Columbia Cancer Agency Genome Sciences Centre platebased and paired-end library protocols on a Microlab NIMBUS liquid handling robot (Hamilton). In brief, 1 μ g of high molecular weight genomic DNA was sonicated (Covaris LE220) in 62.5 μ l volume to 250-350 bp. Sonicated DNA was purified with PCRClean DX magnetic beads (Aline Biosciences). The DNA fragments were end-repaired, phosphorylated and bead-purified in preparation for A-tailing using a custom NEB Paired-End Sample Prep Premix Kit (New England Biolabs). Illumina sequencing adapters were ligated overnight at 16 °C, and adaptor-ligated products were bead-purified and enriched with 6 cycles of PCR using primers containing a hexamer index that enables library pooling. 200 ng for each of 6 different libraries were pooled before whole exome capture using Agilent SureSelect All Exon V6+ UTR probes. The pooled libraries were hybridized to the RNA probes at 65 °C for 24 h. Following hybridization, streptavidin-coated magnetic beads (Dynal, MyOne) were used for exome capture. Post-capture material was purified on MinElute columns (Qiagen) followed by post-capture enrichment with 6 cycles of PCR using primers that maintain the library-specific indices. The pooled libraries were sequenced on an Illumina Hiseq 2500, using V4 sequencing chemistry at PE125 following Illumina recommendations (Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency).
For the GBM-719 xenograft samples, GFP-positive barcoded cells were isolated by fluorescence-activated cell sorting (MoFlo Astrios, Beckman Coulter) from in vitro expanded cells (p3 TMZ TMZ) or directly from dissociated tumours (all remaining samples) and subjected to DNA extraction using a PrepGEM DNA extraction kit (PTI0050, ZyGEM) before whole-genome amplification using a REPLI-g Mini kit (150023, Qiagen). 200 ng of DNA per sample was used to generate cDNA libraries using an Agilent SureSelect XT target enrichment kit as per protocol. 750 ng from each cDNA library was then hybridized for 24 h using the All Exon V5 capture baits from Agilent. Captured, enriched libraries were size-validated using the Agilent Bioanalyzer DNA high sensitivity chip, and the library concentration was validated by qPCR (Kapa Technologies). All libraries were normalized to 10 nM and diluted to 2 nM before being denatured with 0.1 M NaOH. Denatured library pools were diluted for a final time down to 14 pM of pooled libraries and loaded onto an Illumina cBot for cluster generation. The clustered flow cell was pair-end sequenced for 100 cycles using an Illumina HiSeq 2000 (Princess Margaret Genomics Centre, University Health Network).
For the germline reference sample, DNA was extracted from the patient's whole blood using a DNeasy Blood & Tissue kit (69504, Qiagen). The library was prepared using Agilent SureSelect Human Exome Library Preparation V4 kit for paired end sequencing on a HiSeq 2500 platform. In brief, 750 ng of genomic DNA was fragmented to 200-bp on average using a Covaris LE220 instrument. Sheared DNA was end-repaired and the 3′ ends adenylated before ligation of adapters with overhang-T. The genomic library was amplified by PCR (10 cycles) and hybridized with biotinylated probes that target exonic regions; the enriched exome libraries were amplified by an additional 8 cycles of PCR. Exome libraries were validated for size on a Bioanalyzer 2100 DNA High Sensitivity chip (Agilent Technologies) and for quantity by qPCR using the Kapa Library Quantification Illumina/ABI Prism Kit protocol (KAPA Biosystems). Exome libraries were pooled and sequenced with TruSeq SBS sequencing chemistry using a V4 high throughput flowcell on a HiSeq 2500 platform following Illumina's recommended protocol (The Centre for Applied Genomics, The Hospital for Sick Children). Exome sequencing analysis of primary tumours. For the primary tumour samples, Fastq files were aligned to the human reference genome hg38 with BWA (0.7.9a, -M option) 35 . The BAM files were further processed using MarkDuplicates (Picard Tools 2.6.0), indel realignment (GATK 3.6 RealignerTargetCreator and IndelRealigner) and BaseRecalibration (GATK 3.6 BaseRecalibrator and PrintReads) 36 . Samtools 1.3.1 mpileup (-B, -q10 -d10000000 options) 37 was run on the processed BAM files to generate the input to Varscan. Varscan (2.4.2), mpileup2cns was applied to call SNP and indels in each sample (P value 0.01; minimum variable frequency 0.03; other parameters as default 38 . The calls were annotated with Annovar (20160201, using refGene genes) 39 . To identify the important somatic variants, the calls were further filtered to include only the following annotated events: nonsynonymous_SNV, stopgain, stoploss and frameshift_deletion. In addition, calls were removed if they were in the dbSNP database 40 as part of the 'snp147Com-mon' file downloaded from the UCSC server, which contains uniquely mapped variants that appear in at least 1% of the population or are 100% non-reference. Therefore, the flagged SNPs (uniquely mapped variants, excluding common SNPs, that have been flagged by dbSNP as 'clinically associated') were not removed. In addition, calls were further filtered out if they had an allele frequency > 0.001 in ExAC (exac03, ExAC_ALL) 41 or 1000 Genome Project (1000g2015aug_all) 42 . Subclonal mutations with variant allele frequency < 0.2 were excluded. Exome sequencing analysis of xenografts. For the GBM-719 xenograft samples, read pairs were aligned to the hg19 reference sequence using the Burrows-Wheeler Aligner (v0.7.12) 35 , and samples were demultiplexed using Picard tools (v1.140). Data were then sorted and duplicate marked using Picard and SAMtools 37 . Local realignment around insertions or deletions (indels) and base-quality score recalibration was performed using the Genome Analysis toolkit (v3.4-46) 36 . QualiMap (v2.1) 43 was used to evaluate the resulting sequencing alignment data. To correct for coverage discrepancies between Agilent V4 (germline reference sample) and V5 (xenograft samples) capture baits, an intersection of common regions was performed using bedtools (v2.26.0) 44 . Common regions with 0× coverage in the blood or greater than 500× coverage in either reference or xenografts were removed from subsequent analysis.
The MuTect (v.1.15) algorithm 45 was used for somatic variant calling and false-positive filtering. The resulting variants were annotated using Oncotator (v.2.8.0) 46 , including common databased variants (ClinVar 47 , 1000 Genomes (phase 1 variant set) 48 , dbSNP (build 138) 40 and COSMIC (v71) 49 ). Germline variants found in the 1000 Genomes Project, dbSNP build 138 were excluded. Cellularity, ploidy and allele-specific copy number were estimated from normal-xenograft pairs using the Sequenza algorithm (v2.1.2) 50 . Cutoffs of log 2 copy number ratios between − 0.35 and + 0.3 were set to assign genome losses and gains, respectively. RNA sequencing. RNA was extracted from the same flash-frozen primary tumour pieces used for exome sequencing using a Qiagen AllPrep DNA/RNA Mini Kit (80204, Qiagen). The quality of total RNA samples was determined using an Agilent Bioanalyzer RNA Nanochip or Caliper RNA assay and arrayed into a 96-well plate (Thermo Fisher Scientific). Polyadenylated (PolyA+ ) RNA was purified using the NEBNext Poly(A) mRNA Magnetic Isolation Module (E7490L, NEB) from 500 ng total RNA normalized in 35 μ l for DNase I-treatment (1 U, Invitrogen). DNase-treated RNA was purified using RNA MagClean DX beads (Aline Biosciences) on a Microlab NIMBUS liquid handler (Hamilton Robotics). Messenger RNA selection was performed using NEBNext Oligod(T) 25 beads (NEB) with incubation at 65 °C for 5 min followed by snap-chilling at 4 °C to denature RNA and facilitate binding of poly(A) mRNA to the beads. mRNA was eluted in 36 μ l of Tris buffer.
First-strand cDNA was synthesized from the purified polyadenylated messenger RNA using the Maxima H Minus First Strand cDNA Synthesis kit (Thermo Fisher) and random hexamer primers at a concentration of 5 μ M along with a final concentration of 1 μ g μ l −1 Actinomycin D, followed by PCR Clean DX bead purification on a Microlab NIMBUS robot (Hamilton Robotics). The second-strand cDNA was synthesized following the NEBNext Ultra Directional Second Strand cDNA Synthesis protocol (NEB) that incorporates dUTP in the dNTP mix, allowing the second strand to be digested using USER enzyme (NEB) in the post-adaptor ligation reaction and thus achieving strand specificity.
cDNA was fragmented by sonication (Covaris LE220) for 55 s at a duty cycle of 20% and an intensity of 5 to achieve fragment lengths of 200-250 bp on average. The paired-end sequencing library was prepared following the BC Cancer Agency Genome Sciences Centre strand-specific, plate-based library construction protocol on a Microlab NIMBUS robot (Hamilton Robotics). In brief, the sheared cDNA was subject to end-repair and phosphorylation in a single reaction using an enzyme premix (NEB) containing T4 DNA polymerase, Klenow DNA Polymerase and T4 polynucleotide kinase, incubated at 20 °C for 30 min. Repaired cDNA was article reSearcH purified in a 96-well plate using PCR Clean DX beads (Aline Biosciences), and 3′ A-tailed (adenylation) using Klenow fragment (3′ to 5′ exo minus) and incubation at 37 °C for 30 min before enzyme heat inactivation. Illumina PE adapters were ligated at 20 °C for 15 min. The adaptor-ligated products were purified using PCR Clean DX beads, then digested with USER enzyme (1 U per μ l, NEB) at 37 °C for 15 min, followed immediately by 13 cycles of indexed PCR using Phusion DNA Polymerase (Thermo Fisher Scientific Inc.) and Illumina's PE primer set. PCR parameters: 98 °C for 1 min followed by 13 cycles of 98 °C 15 s, 65 °C 30 s and 72 °C 30 s, and then 72 °C 5 min. The PCR products were purified and size-selected using a 1:1 PCR Clean DX beads-to-sample ratio (twice), and the eluted DNA quality was assessed with Caliper LabChip GX for DNA samples using the High Sensitivity Assay (PerkinElmer, Inc.) and quantified using a Quant-iT dsDNA High Sensitivity Assay Kit on a Qubit fluorometer (Invitrogen) before library pooling and sizecorrected final molar concentration calculation for Illumina HiSeq 2500 sequencing with paired-end 75 base reads (Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency). RNA sequencing analysis. Fastq files were aligned with STAR (2.4.2a) 51 on the hg38 human reference genome. FPKM values were computed with the DESeq2 fpkm function 52 using the raw read count per gene (ReadsPerGene.out.tab file from STAR output), with size factor normalization and gene length derived from the hg38 GTF files used for the alignment. Subgroup classification was done using the simple GBM classifier 53 . This 32-gene classifier permits greater accuracy of GBM subgroup classification when using RNA-seq data instead of gene expression microarrays, as was performed in the original subgrouping study 20 . One of the 32 genes was not quantified in the analysis so the classifier was run using 31 genes.
Assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq).
The open chromatin profiles of 11 GSC lines were defined using ATAC-seq as described previously 54 and the prepared libraries were sequenced with 50-bp single end reads. Reads were mapped to hg19 using bowtie2 55 and peaks of open chromatin were called with MACS2 56 . The correlation between samples was calculated as the Pearson correlation of the quantile-normalized signal across the peak catalogue. Here, the peak catalogue corresponds to all peak regions identified across the sample cohort, and the signal refers to the fold enrichment of the signal per million reads in a sample over a modelled local background. The chronic lymphocytic leukaemia data used in this comparison were taken from a published dataset 57 , and the raw signal was normalized together with the GSC cohort. MGMT promoter methylation assay. Primary tumour DNA was subjected to bisulfite conversion using the EZ DNA Methylation-Gold Kit (D5005, Zymo Research), and MGMT promoter methylation status was assessed using a two-step PCR protocol as previously described 58 . PCR products, including water control, were visualized by electrophoresis on a 2% agarose gel along with a 100-base-pair ladder (NEB). Lentiviral barcoding. The lentiviral barcode library has been described previously 15 . For viral transduction, 1 × 10 6 primary GBM cells were seeded per plate onto 10-cm cell culture dishes coated with poly-l-ornithine (PLO, Sigma) and laminin (Sigma). The culture media consisted of serum-free Neurocult NS-A Basal (StemCell Technologies) media, supplemented with 2 mmol l −1 l-glutamine, N2 and B27 supplements, 75 μ g bovine serum albumin, 10 ng ml −1 recombinant human EGF, 10 ng ml −1 basic fibroblast growth factor, and 2 μ g ml −1 heparin (Sigma) 26 . Primary cells were incubated for approximately 12 h at 37 °C with lentivirus at an appropriate concentration to minimize multiple integration events. The concentration of lentivirus used was previously determined by titrating the library with a human fetal-derived neural stem cell culture (HF7450), and assessing GFP positivity by flow cytometry (LSR II, BD Biosciences) 48 h post-transduction. Barcoded cells were washed five times with PBS to remove remaining lentivirus, and immediately harvested by accutase (Sigma) treatment for orthotopic injection. A separate cell aliquot was cultured for 48 h to allow for GFP expression, and transduction efficiency was determined by flow cytometry (LSR II, BD Biosciences). Mouse xenografts. All mouse procedures were approved by The Hospital for Sick Children's Animal Care Committee. For intracranial injections, animals were first anesthetized with isoflurane and given ketoprofen as an analgesic. Tumour cells were then suspended in a 2-μ l volume of PBS and injected into the forebrains of female NOD/SCID IL2Rγ − (NSG) mice aged 1-3 months with a Hamilton syringe and stereotactic device. The coordinates for orthotropic injections are 4 mm anterior of lambda, 2 mm to the right of the midline, and 3 mm deep. For secondary and tertiary xenografts, 25 mg kg −1 TMZ (Sigma) solubilized in Cremophor or vehicle controls were administered by gastric gavage for 5 consecutive days, 10 days post-injection. Mice were euthanized for further processing once neurological symptoms were observed, or at the experiment endpoint (six months). Survival analysis was performed using GraphPad Prism 5 software. Processing of xenografts. Forebrains were obtained from animals displaying neurological symptoms, and the two hemispheres (ipsilateral and contralateral) were dissected for processing separately. Each hemisphere was dissociated to single-cell suspensions as described in the 'Processing of patient samples' section. Cells were subsequently subjected to magnetic bead depletion to remove contaminating mouse cells (130-104-694, Miltenyi Biotech) before serial transplantation. Serial xenografts were always established without any intermediate culturing step. Either the ipsilateral or contralateral fraction from a single mouse was used to establish serial xenografts. Approximately 15% of xenograft cells were used without magnetic bead depletion for PCR amplification, library preparation and deep amplicon sequencing of barcodes. One xenograft per experimental group was set aside for histological analysis. Splinkerette PCR according to a previously published protocol 59 was performed in order to identify unique barcode vector integration sites from xenografts. Histopathology and immunohistochemistry. Mouse brains were fixed in 4% paraformaldehyde (PFA), washed in 70% ethanol and paraffin-embedded. 6-μ m coronal sections were generated for further analysis. Haematoxylin and eosin staining was carried out according to manufacturer's instructions (MHS32-1L, SigmaAldrich and 6766009, Thermo Scientific). Antibodies for immunohistochemistry include anti-nestin (MAB5326, Millipore; used at 1:500), anti-Ki-67 (M7240, Dako; used at 1:500) and anti-cleaved caspase-3 (9661, Cell Signaling; used at 1:500). A secondary anti-mouse HRP antibody (A9044, Sigma; used at 1:500) was used for detection using 3,3′ -diaminobenzidine (DAB), alkaline phosphatase (AP) and mouse on mouse (M.O.M) detection kits (Vector Laboratories). Images were acquired using a 3DHistech Pannoramic 250 Flash II Slide Scanner and processed using Pannoramic Viewer software (3DHISTECH). Automatic detection and quantification of Ki-67 and cleaved caspase-3 staining was performed on six representative images per sample, using TMARKER software 60 . Barcode sequencing. Spiked-in controls were generated using a human fetalderived neural stem cell line (HF7450) using the previously described protocol 15 , and combined into single wells of a 96-well plate. For the GBM-719 experiment and the first sequencing run, the cell numbers used as spiked-in controls were 10, 100, 250, 500, and 5,000. For all subsequent in vivo experiments and the second sequencing run, the cell numbers used were 10, 100, and 5,000. For all in vitro experiments and the third sequencing run, the cell numbers used were 10, 100, 500, and 5,000. Separate spiked-in control-only wells containing barcode sequences derived from 25,000 and 100,000 cells were also included in the GBM-719 experiment, to test accuracy of extrapolation for larger clones. The same was done in the third sequencing run for in vitro experiments, using a control of 50,000 cells. Xenograft samples were combined with spiked-in controls and subjected to DNA extraction using a PrepGEM DNA extraction kit (PTI0050, ZyGEM) followed by ethanol precipitation and deep amplicon sequencing as described previously 15 . In brief, a two-step PCR protocol was used to generate barcode amplicons with fault-tolerant sample indices, and equimolar samples were pooled and loaded onto a single lane of a flow cell for paired-end sequencing on the Illumina MiSeq platform (Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency). Barcode data analysis. Barcode sequences were extracted from raw data files with custom scripts, and those with a minimum base quality of 20 that matched the flanking regions (with up to 3 mismatches) surrounding the barcode sequence were kept. A merging of highly similar barcodes was performed in order to limit the number of false positive barcode sequences that may arise from sequencing errors 61 . Specifically, a list of read counts corresponding to all unique barcode sequences was generated, and read counts corresponding to sequences with up to three mismatches were combined into the most abundant sequence. Barcode sequence logograms were generated using the R package ggseqlogo (https://github. com/omarwagih/ggseqlogo). Spiked-in controls were retrieved for defining noise thresholds and clone size estimation as described previously 16, 22 . We defined fractional read value (FRV) as the read count for a particular barcode sequence divided by the sum read counts of all spiked-in controls in the sample. A relationship was generated between FRVs and control cell number for spiked-in controls across all samples. A Cook's distance of 4/n was used to define outlier controls and the relationship was generated again with those outliers removed to estimate clone sizes. This step was performed to ensure that outlier controls do not influence the estimation of relative clone sizes in the majority of samples within a particular sequencing run. FRV thresholds were determined from spiked-in controls in order to maximize the difference between the true positive rate and false positive rate, and only clones with FRVs greater than the threshold were kept. The total cell number for each sample was estimated by summing up estimated cell numbers for each clone in the sample that are above detection threshold. Relative clone sizes were then determined by dividing the cell numbers for each clone by the total cell number calculated for each sample. Proportional Venn diagrams for barcode sequences were generated with eulerAPE v3 software 62 . Generation of xenograft-derived cultures. Dissociated primary GBM xenografts were cultured as described in the 'lentiviral barcoding' section after depletion article reSearcH of contaminating mouse cells (130-104-694, Miltenyi Biotech). All short-term cultures were subjected to two to three passages before barcode sequencing. Short-term cultures were not subjected to mycoplasma testing or microsatellite genotyping, although in all cases the identified barcode sequences of cultures matched those of the corresponding xenograft series. Cell culture assays. For proliferation assays, GSCs were propagated for 11 days in triplicate under previously described conditions 26 . Viable cells were counted on days 0, 2, 4, 7, 9, and 11 with a Countess Automated Cell Counter (Thermo Fisher Scientific), excluding apoptotic cells that stained positive for trypan blue (Thermo Fisher Scientific). Doubling times were calculated during exponential growth phase (between days 4 and 11) using the formula t/log 10 2 × log 10 (N t2 /N t1 ), where N t1 and N t2 are the number of cells on days 4 and 11 respectively and t is the elapsed time in hours. For dosage response assays, GSCs were cultured with drug for five days with six technical replicates per dose, without any media changes. Cell viability relative to DMSO control was then assessed by AlamarBlue assay (Thermo Fisher Scientific) using a Gemini EM Fluorescence Microplate Reader (Molecular Devices). Drug screening. Primary drug screens were carried out in 96-well format on passage 2-3 cultures that were grown under previously described conditions 26 . An Incucyte Zoom live-cell analysis system (Essen Bioscience) was used to quantify confluency according to the manufacturer's instructions. In order to characterize drug responsiveness of barcoded clones, a second screen was performed in which cells were seeded on 6-well plates, subjected to a single round of drug selection in duplicate, and harvested for barcode sequencing when the culture reached approximately the same confluency as DMSO controls (around 90%). In this assay, culture media was refreshed every three days without drug. The concentrations of drugs used for screening were as follows: rapamycin: 20 nM, dasatinib: 125 nM, BIO; daunorubicin: 1 μ M, LGK-974; RO4929097; WP1066: 2 μ M, imatinib: 2.5 μ M, bromosporine; CI-994; GSK591; GSK-J4; GSK-LSD1; InSolution γ -secretase inhibitor X; IOX2; JQ-1; L-741,742; LAQ824; MI-2-2; MS023; OF-1; olaparib; PFI-1; PNU96515E; SGC-CBP30; UNC1999: 5 μ M, erlotinib: 10 μ M, TMZ: 50 μ M. Once around 90% confluency was reached, all surviving cells were used for DNA extraction and barcode sequencing as described above. Limiting dilution analysis. Cells were plated onto flat-bottom 96-well plates (Sarstedt) in 100 μ l of culture media, 6 replicates per cell dose. The culturing conditions are described previously 26 , with the exception that culture plates were not coated with PLO and laminin to allow for sphere formation. For analysis of primary, uncultured GBM cells, twofold dilutions from 4,000 cells to 8 cells were used and scored after 2 weeks of culture. For analysis of established GSC cultures, twofold dilutions from 2,000 cells to 4 cells were used and scored after 1 to 2 weeks of culture. Drugs were added only once on the first day at either 1 μ M or 5 μ M as indicated for each experiment, with 50 μ l of fresh media added to each well after the first week. Investigators were blinded to the label for each plate during data collection. Data were analysed using ELDA software MI-2-2 (444825, Millipore) or vehicle control (15% DMSO, 25% PEG, 60% PBS) for 2 weeks by intraperitoneal injection. The treatment schedule was Monday, Wednesday, Friday of each week for a total of six treatments. Mice were then monitored for tumour formation and euthanized once the control tumours reached endpoint for measurement (127 days between injection and euthanasia). Flanks in which tumours were not visible were excluded from analysis. Subcutaneous tumour size did not exceed the limit set by the experimental protocol with The Hospital for Sick Children's Animal Care Committee (17 mm in the longest dimension). Stochastic simulations. A standard stochastic simulation algorithm 63 was used to simulate realizations of the stochastic process defined by the model shown in Fig. 2c and described fully in Supplementary Theory 5. Clone size distributions, clone size cross correlations and the ratio of surviving clones were then calculated from 100,000 realizations of the system for each parameter set. To compare the model with experiments, we simulated the system using 108 equidistant parameter sets located in the region of biologically plausible parameters and compared the results to experimental data points. 
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Data exclusions
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NSG mice from separate litters were randomized to vehicle control or TMZ treatment groups in order to control for age.
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